Vimarsana
Biggest News Aggregation in the World

Page 19 - Genomic Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genomic Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genomic Sciences Today - Breaking & Trending Today

Research from the University of Birmingham, U.K., identifies new treatment target for CNS injury and neurological disease - Vimarsana News

Research from the University of Birmingham, U.K., identifies new treatment target for CNS injury and neurological disease

/PRNewswire/ -- Birmingham researchers have identified a potential target for drugs to treat long-term neurological conditions like Alzheimer's Disease and...

Scientists reverse the effects of lysosomal storage disorders in patient cells and mice - Vimarsana News

Scientists reverse the effects of lysosomal storage disorders in patient cells and mice

Scientists at the Icahn School of Medicine at Mount Sinai in New York, the National Center for Advancing Translational Sciences (NCATS), and elsewhere have reversed the effects of several life-threatening inherited neurodegenerative diseases called lysosomal storage disorders (LSDs) in patient cells and mice.

HARMONIC DISCOVERY LAUNCHES WITH $8 MILLION IN SEED TO DEVELOP A NEW GENERATION OF MULTI-TARGET KINASE INHIBITORS - Vimarsana News

HARMONIC DISCOVERY LAUNCHES WITH $8 MILLION IN SEED TO DEVELOP A NEW GENERATION OF MULTI-TARGET KINASE INHIBITORS

/PRNewswire/ -- Harmonic Discovery, a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and...

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated a-gal A Enzyme Activity in Five Longest Treated Patients - Vimarsana News

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated a-gal A Enzyme Activity in Five Longest Treated Patients

Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the six treated patients The five longest treated patients exhibited elevated a-Gal A activity

Innovation Endeavors Brings on Dr. Joel Dudley as a - Vimarsana News

Innovation Endeavors Brings on Dr. Joel Dudley as a

Signals firm's commitment to investing in biotech, biology, and computational 'super evolution' breakthroughs...